Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT07575932
Active, not recruiting Phase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

NCT07575932 · tracked via the Priya Life Science Canada tracker
Sponsor
Pfizer
Phase
Phase 2
Started
2026-05-11
Last updated
2026-09-14

Condition(s) studied

OverweightObesityOverweight and/or ObesityOverweight or ObesityOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody Weight

Investigational drug(s) / intervention(s)

PF-08653945 →PF-08653944 →Placebo

PF-08653945: Subcutaneous Injection

PF-08653944: Subcutaneous Injection

Placebo: Subcutaneous Injection

Study summary

This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Eligible participants for this study include: * adults aged 18 years or older with * obesity (BMI of 30.0 kg/m2 to 50.0 kg/m2) or with * overweight (BMI of 27.0 kg/m2 to \<30.0 kg/m2) who also have at least 1 prespecified weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea), at the screening visit. Exclusion Criteria: Participants who are not eligible include those with diabetes mellitus, a body weight change of \>5% or use of weight loss medications in the 12 weeks prior to screening, a history of or plan for surgical treatment for obesity, and those who are unable or unwilling to comply with contraceptive requirements or are pregnant or lactating.

Primary outcome measure(s)

Trial sites (63)

FacilityCityRegionStatus
Clinical Research Institute of Arizona Sun City West Arizona
San Fernando Valley Health Institute Canoga Park California
Ark Clinical Research Fountain Valley California
Paragon Rx Clinical Garden Grove California
Torrance Clinical Research Institute, Inc. Lomita California
Ark Clinical Research Long Beach California
Collaborative Neuroscience Research, LLC Los Alamitos California
Paradigm Clinical Research-Modesto Modesto California
Paradigm Clinical Research Centers, LLC San Diego California
University Clinical Investigators, Incorporated Tustin California
Diablo Clinical Research, LLC dba Flourish Research Walnut Creek California
AGA Clinical Trials Hialeah Florida
Westside Center for Clinical Research Jacksonville Florida
New Horizon Research Center Miami Florida
Charter Research Orlando Florida
Atlanta Diabetes Associates Atlanta Georgia
Clinical Research Atlanta Stockbridge Georgia
Koch Family Medicine Clinical Research/Elite Research Network Morton Illinois
Bioluminux Clinical Research Illinois Naperville Illinois
Johnson County Clinical Trials Lenexa Kansas
DelRicht Research Mandeville Louisiana
DelRicht Research Prairieville Louisiana
Patient First Clinical Trials (PFCTRIALS) Lutherville Maryland
DelRicht Research Springfield Missouri
Mercury Street Medical Group, PLLC Butte Montana
Alliance Clinical Research Las Vegas (Excel Clinical Research) Las Vegas Nevada
AB Clinical Trials Las Vegas Nevada
Palm Research Center Las Vegas Nevada
Bioluminux Clinical Research Hamilton New Jersey
DelRicht Research Charlotte North Carolina
Monroe Biomedical Research Monroe North Carolina
Piedmont Healthcare Statesville North Carolina
Accellacare - Wilmington Wilmington North Carolina
Tekton Research, LLC. Oklahoma City Oklahoma
Preferred Primary Care Physicians Pittsburgh Pennsylvania
Preferred Primary Care Physicians, Inc. Uniontown Pennsylvania
Preferred Primary Care Physicians Uniontown Pennsylvania
TMA Headlands LLC (d/b/a Trial Management Associates) Myrtle Beach South Carolina
DelRicht Research Hendersonville Tennessee
Cedar Health Research - Euless Euless Texas

+ 23 more sites — see the full list on the official registry below.

More Pfizer trials in Canada

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia Recruiting
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B Active, not recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine Recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC Active, not recruiting
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) Active, not recruiting

Other trials for the same condition

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight Active, not recruiting
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss Active, not recruiting
Magnetic Gastro-Ileal or Gastro-Jejunal Diversion Study ("MGI/MGJ Study") Active, not recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes Recruiting
MagDI Canada Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07575932 on ClinicalTrials.gov ↗ ← All trials in Canada